Howard Horn
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Howard Horn
Howard Horn is recorded as CFO at Ultragenyx Pharmaceutical Inc. (RARE). Ultragenyx Pharmaceutical Inc. reported in an 8-K filed September 8, 2023 that Howard Horn was appointed Chief Financial Officer and Executive Vice President, Corporate Strategy, effective October 9, 2023. Ultragenyx Pharmaceutical Inc. reported in an 8-K filed July 12, 2023 that Howard Horn was appointed Chief Financial Officer and Executive Vice President, Corporate Strategy, effective October 16, 2023. The proxy statement of Ultragenyx Pharmaceutical Inc. reports total compensation of $3,750,607 for Howard Horn in fiscal 2025, including a base salary of $604,385. Disclosed compensation is on record for 3 fiscal years. Howard Horn has spoken on 10 earnings calls and 2 other investor events across 1 company, most recently for Ultragenyx Pharmaceutical Inc. on September 17, 2026.
“Mr. Horn and the Company have modified the effective date of Mr. Horn's appointment as the Company's CFO and EVP, Corporate Strategy from October 16, 2023 to October 9, 2023”
“On July 12, 2023, Ultragenyx Pharmaceutical Inc. (the "Company") announced that Howard Horn has been appointed as the Company's Chief Financial Officer and Executive Vice President, Corporate Strategy, effective as of October 16, 2023 (the "Effective Date").”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
Start not stated–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Ultragenyx Pharmaceutical Inc.
Other people whose current roles at this company are on record from its filings.
- Emil D. Kakkis CEO, Board Member
- Emil Kakkis CEO, Board Member
- Eric Crombez, M.D. CTO
- Karah Parschauer General Counsel
- Amrit Ray, M.D. Board Member
- Clay B. Siegall Board Member
- Continuing Directors Board Member
- Corazon (Corsee) D. Sanders, Ph.D. Board Member
- Corsee Sanders, Ph.D. Board Member
- Daniel G. Welch Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Ultragenyx Pharmaceutical Inc. (RARE) | Chief Financial Officer, Corporate Strategy and Executive Vice President | $604,385 | $3,750,607 |
| 2024 | Ultragenyx Pharmaceutical Inc. (RARE) | Chief Financial Officer, Corporate Strategy and Executive Vice President | $590,000 | $4,296,049 |
| 2023 | Ultragenyx Pharmaceutical Inc. (RARE) | Chief Financial Officer, Corporate Strategy and Executive Vice President | $124,808 | $5,941,040 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.